Sanofi continues Latin American swing
This article was originally published in The Tan Sheet
Executive Summary
Sanofi-Aventis acquires Brazilian generic drug maker Medley, which it values at 500 million Euros ($662.3 million by April 10 conversion rates). The addition of Medley's 127 generic products, including OTC drugs, will make Sanofi the No. 1 pharma company in Brazil, with 12 percent market share, the Paris-based firm said in an April 9 release. Medley's 2008 sales reached $202.7 million. Sanofi added it expects Brazil's generics market to grow 20 percent annually in the coming years. The firm reached into Brazil a week after acquiring Mexican generics firm Laboratorios Kendrick (1"The Tan Sheet" April 6, 2009, In Brief)
You may also be interested in...
Sanofi-Aventis acquires Mexican firm
The Paris-based firm acquires Laboratorios Kendrick and plans to fold the generics firm into its existing Mexican generics business. The April 2 deal gives Sanofi more than 50 active pharmaceutical ingredients in Kendrick's portfolio, including the antihistamine loratadine. Kendrick's sales reached around 500 million pesos in 2008. Sanofi also expanded its global OTC business with the recent acquisition of Czech firm Zentiva (1"The Tan Sheet" Feb. 16, 2009, p. 6)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.